Anaptysbio (ANAB) Net Cash Flow (2016 - 2026)
Anaptysbio's (ANAB) quarterly Net Cash Flow came in at $10.3 million in Q1 2026, up 142.03% YoY from $4.2 million in Q1 2025, and down 92.0% on a QoQ basis from $128.4 million in Q4 2025.
Anaptysbio (ANAB) Net Cash Flow (2016 - 2026) Analysis & Trends
Anaptysbio (ANAB) has 11 years of Net Cash Flow data on file, last reported at $10.3 million in Q1 2026.
- Quarterly Net Cash Flow rose 142.03% year-over-year to $10.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $149.8 million (up 233.39% YoY) and the FY2025 annual result came in at $115.1 million, up 32.14% from the prior year.
- Net Cash Flow eased to $10.3 million in Q1 2026, from $128.4 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $128.4 million in Q4 2025 to a low of -$329.3 million in Q1 2022.
- A 5-year average of -$14.5 million and a median of $9.7 million in 2023 frame the typical range for Net Cash Flow.
- Annual changes were most pronounced in 2022 — Net Cash Flow slumped 1077.43% — and 2024, when it surged 1443.96%.
- Tracing ANAB's Net Cash Flow over 5 years: stood at $12.8 million in 2022, then slipped by 24.22% to $9.7 million in 2023, then plunged by 808.39% to -$68.5 million in 2024, then soared by 287.39% to $128.4 million in 2025, then slumped by 92.0% to $10.3 million in 2026.
- The last three Net Cash Flow figures came in at $10.3 million (Q1 2026), $128.4 million (Q4 2025), and $65.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Anaptysbio | 1.70 Bn | 1.41 Bn | - | 10.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.27 Mn |
| Mar 31, 2026 | 10.27 Mn |
| Dec 31, 2025 | 128.36 Mn |
| Dec 31, 2025 | 128.36 Mn |
| Sep 30, 2025 | 65.54 Mn |
| Sep 30, 2025 | 65.54 Mn |
| Jun 30, 2025 | -54.34 Mn |
| Jun 30, 2025 | -54.34 Mn |
| Mar 31, 2025 | -24.44 Mn |
| Mar 31, 2025 | -24.44 Mn |
| Dec 31, 2024 | -68.50 Mn |
| Dec 31, 2024 | -68.50 Mn |
| Sep 30, 2024 | 119.76 Mn |
| Sep 30, 2024 | 119.76 Mn |
| Jun 30, 2024 | 18.13 Mn |
| Jun 30, 2024 | 18.13 Mn |
| Mar 31, 2024 | 17.73 Mn |
| Mar 31, 2024 | 17.73 Mn |
| Dec 31, 2023 | 9.67 Mn |
| Dec 31, 2023 | 9.67 Mn |